Newron Pharmaceuticals SpA ( (CH:NWRN) ) has provided an announcement.
Newron Pharmaceuticals reported significant progress in 2024, highlighted by promising data from studies on Evenamide, a potential treatment for schizophrenia. The company secured strategic licensing agreements with EA Pharma and Myung In Pharm, enhancing its market presence in Asia and supporting its upcoming Phase III study. With a net profit of EUR 15.8 million, Newron is poised for further growth in 2025, driven by its robust financial position and strategic partnerships.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company specializing in the development of innovative therapies for central and peripheral nervous system disorders. The company focuses on creating novel treatment options for conditions like schizophrenia, aiming to address unmet medical needs in this field.
Technical Sentiment Signal: Sell
Current Market Cap: $181.1M
For an in-depth examination of NWRN stock, go to TipRanks’ Stock Analysis page.